Jump to content

Property:Exclusion criteria

From CAMIH

This is a property of type Text.

Showing 20 pages using this property.
K
Immunosuppressed patients; patients with genetic skin cancer disorders and tumors in the face and/or hairy scalp  +
Patients with significant cardiac, renal or neurologic comorbidities, or an active state of malnutrition, diabetes, pregnancy, and Karnofsky index less than 70  +
Patients with history of ginger hypersensitivity, pregnancy or breast-feeding, and previous chemotherapy; patients with access to aprepitant or fosaprepitant; patients with poor blood values (e.g. AST, ALT, creatinine)  +
Prior exposure to neurotoxic, not have had any of the following conditions: coronary artery disease, congestive heart failure, diabetes (requiring pharmacologic intervention), head or neck cancers, or a history of a hemorrhagic stroke, pregnant or nursing women, concomitant use of anticoagulants, platelet aggregation inhibitors, opioids, anticonvulsants, tricyclic antidepressants, other neuropathic pain medication agents, or vitamin E, not have been receiving radiation  +
Liver dysfunction, respiratory dysfunction, cardiac dysfunction, renal failure, ongoing infection, history of recent immunosuppressive or immunologic disease (including preoperative chemo-therapy and/or radiation therapy), or diabetes mellitus  +
Liver failure, a second malignancy, treatment with omega-3-fatty acids and the presence of a mental disorder precluding informed consent  +
L
Allergy to ginger; pregnancy or lactation; current radiotherapy; preexisting nausea or vomiting from any cause; the presence of other diseases as a possible cause of nausea or vomiting (hepatitis, gastrointestinal obstruction, or diseases); use of coumadin or heparin for therapeutic anticoagulation; blood disorders or a platelet count <100 000/µL  +
Fungating malignant wound with fistula, sinus or exposure of bone; patients receiving systemic metronidazole; patients treated with topical metronidazole for more than 30 days and neutropenic patients with total white cell count of less than 1.5×109/L.  +
Baseline use of morphine at >500 mg morphine equivalents/day (inclusive of maintenance and breakthrough opioids); current use of more than one type of breakthrough opioid analgesic; planned clinical interventions that would affect pain; any history of schizophrenia or substance abuse  +
Previous chemotherapy; brain metastasis; double tumour; lack of tolerance to polychemotherapy due to performance status, age or comorbidities  +
Presence of distant metastases; a previous history of salivary gland disorders, collagen tissue disease, diabetes, previous 131I therapy, or external radiation to the head or neck; or difficulty drinking a large amount of water.  +
Patients with other malignancies, being allergic to ginger, perfumes or cosmetics or patients undergoing concurrent radiotherapy  +